drugset / Trial / NCT00640848

Almorexant in Primary Insomnia

NCT00640848

Phase 1 Completed 161 enrolled Midnight Pharma, LLC
RandomizedCrossoverQuadruple-blindTreatment

Summary

The aim of the study is to determine the minimum effective dose of ACT-078573 on sleep efficiency and to assess the effects of different doses of ACT-078573 on other PSG parameters.

Timeline

Start
2006-05
Primary completion
2007-08
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject almorexant Small molecule 50 mg
Subject almorexant Small molecule 100 mg
Subject almorexant Small molecule 200 mg
Subject almorexant Small molecule 400 mg
Subject almorexant Small molecule 1000 mg

Indications